Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
在 AACR 演讲中获得积极的 PH-894 临床前数据后，Phio Pharma 股价大放异彩
Phio Pharmaceuticals Corp (NASDAQ:PHIO) has presented new preclinical data for PH-894, a self-delivering RNAi compound targeting the bromodomain-containing protein 4 (BRD4)
Phio 制药公司纳斯达克股票代码：PHIO）公布了 PH-894 的新临床前数据，这是一种靶向含溴域蛋白 4 (BRD4) 的自给药 RNAI 化合物
- The preclinical data exhibited that PH-894 inhibits tumor growth in both PD-1 inhibition responsive and PD-1 inhibition insensitive models.
- The data will be presented at the American Association for Cancer Research (AACR) Annual Meeting.
- In both models, after local administration, strong antitumor efficacy was seen in directly treated and distal, untreated tumors.
- Also Read: Phio Pharma Shares Are Moving Higher On INTASYL Preclinical Data At ESMO Presentation.
- Additionally, intratumoral treatment with PH-894 enhanced the antitumor efficacy of systemic anti-PD-1 antibody therapy, not only for the PH-894 locally treated tumors but also for the PH-894 untreated distal tumors.
- In the PD-1 inhibition insensitive model, local PH-894 therapy was shown to be efficacious as a systemic anti-PD-1 antibody treatment and enhanced the antitumor efficacy of anti-PD-1 therapy when used together.
- Price Action: PHIO shares are up 59.9% at $1.45 during the market session on the last check Friday.
- 临床前数据表明，在 PD-1 抑制响应模型和 PD-1 抑制不敏感模型中，PH-894 都能抑制肿瘤的生长。
- 这些数据将在美国癌症研究协会（AACR）年会上公布。
- 在这两种模型中，局部给药后，在直接治疗的和远端未经治疗的肿瘤中均显示出很强的抗肿瘤疗效。
- 另请阅读： 根据ESMO演讲上的INTASYL临床前数据，Phio Pharma的股价正在走高。
- 此外，使用 PH-894 进行瘤内治疗增强了全身性抗 PD-1 抗体疗法的抗肿瘤疗效，不仅适用于局部治疗的 PH-894 肿瘤，还适用于未经治疗的 PH-894 远端肿瘤。
- 在 PD-1 抑制不敏感模型中，事实证明，局部 PH-894 疗法作为全身性抗 PD-1 抗体治疗是有效的，并且联合使用可增强抗 PD-1 疗法的抗肿瘤疗效。
- 价格走势：在周五最后一次支票的市场交易中，PHIO股价上涨了59.9％，至1.45美元。